Soligenix to present data

Soligenix Inc. (Nasdaq: SNGX) will present results from its ricin toxin vaccine development program at the 20th Annual Conference on Vaccine Research on April 25. Shares of the biopharmaceutical leaped $1.12 to close at $3.69.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.